Cargando…
SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases
BACKGROUND: Until now, FISH has been the gold standard technique to identify HER2 amplification status in ambiguous cases of breast cancer. Alternative techniques have been developed to increase the capacities of investigating HER2 amplification status. The aims of this multicenter study in a large...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3729815/ https://www.ncbi.nlm.nih.gov/pubmed/23875536 http://dx.doi.org/10.1186/1471-2407-13-351 |
_version_ | 1782278995421691904 |
---|---|
author | Jacquemier, Jocelyne Spyratos, Frédérique Esterni, Benjamin Mozziconacci, Marie-Joëlle Antoine, Martine Arnould, Laurent Lizard, Sarab Bertheau, Philippe Lehmann-Che, Jacqueline Fournier, Cécile Blanc Krieger, Sophie Bibeau, Frédéric Lamy, Pierre-Jean Chenard, Marie Pierre Legrain, Michèle Guinebretière, Jean-Marc Loussouarn, Delphine MacGrogan, Gaëtan Hostein, Isabelle Mathieu, Marie Christine Lacroix, Ludovic Valent, Alexander Robin, Yves Marie Revillion, Françoise Triki, Magali Lacroix Seaume, Aline Salomon, Anne Vincent de Cremoux, Patricia Portefaix, Geneviève Xerri, Luc Vacher, Sophie Bièche, Ivan Penault-Llorca, Frédérique |
author_facet | Jacquemier, Jocelyne Spyratos, Frédérique Esterni, Benjamin Mozziconacci, Marie-Joëlle Antoine, Martine Arnould, Laurent Lizard, Sarab Bertheau, Philippe Lehmann-Che, Jacqueline Fournier, Cécile Blanc Krieger, Sophie Bibeau, Frédéric Lamy, Pierre-Jean Chenard, Marie Pierre Legrain, Michèle Guinebretière, Jean-Marc Loussouarn, Delphine MacGrogan, Gaëtan Hostein, Isabelle Mathieu, Marie Christine Lacroix, Ludovic Valent, Alexander Robin, Yves Marie Revillion, Françoise Triki, Magali Lacroix Seaume, Aline Salomon, Anne Vincent de Cremoux, Patricia Portefaix, Geneviève Xerri, Luc Vacher, Sophie Bièche, Ivan Penault-Llorca, Frédérique |
author_sort | Jacquemier, Jocelyne |
collection | PubMed |
description | BACKGROUND: Until now, FISH has been the gold standard technique to identify HER2 amplification status in ambiguous cases of breast cancer. Alternative techniques have been developed to increase the capacities of investigating HER2 amplification status. The aims of this multicenter study in a large series of breast cancer patients were to prospectively compare the level of performance of CISH, SISH, and qPCR alternative techniques on paraffin-embedded core biopsies with “gold standard FISH” for evaluation of HER2 amplification status. METHODS: This study was performed on 840 cases scored by immunohistochemistry (IHC): 0=317 (38%), 1+=183 (22%), 2+=109 (13%), 3+=231 (27%). Each of the 15 French centers participating in the study analyzed 56 breast carcinoma cases diagnosed on fixed paraffin-embedded core biopsies. HER2 amplification status was determined by commercially available FISH used as the reference technique with determination of the HER2/CEN17 ratio or HER2 copy number status. The alternative techniques performed on the same cases were commercially available SISH or CISH and a common qPCR method especially designed for the study including a set of 10 primer pairs: 2 for HER2 (exons 8 and 26), 5 to evaluate chromosome 17 polysomy TAOK1, UTP6, MRM1, MKS1, SSTR2 and 3 for diploidy control TSN, LAP3 and ADAMTS16. RESULTS: The concordance between IHC and FISH was 96% to 95% based on the HER2/CEN17 ratio (n=766) or HER2 copy number (n=840), respectively. The concordance of the alternative techniques with FISH was excellent: 97% and 98% for SISH (498 and 587 cases), 98% and 75% for CISH (108 and 204 cases) and 95% and 93% (699 and 773 cases) for qPCR based on the HER2/CEN17 ratio or HER2 copy number, respectively. Similarly, sensitivity ranged from 99% to 95% for SISH, 100% to 99% for CISH and 89% to 80% for qPCR. The concordance with FISH (ratio) in the 2+ cases was 89% for SISH, 100% for CISH and 93% for qPCR. CONCLUSION: These alternative techniques showed an excellent concordance with FISH in core biopsies allowing their use in routine clinical practice. This newly designed qPCR on paraffin-embedded core biopsies deserves special attention, as it is reliable, easy to perform and less expensive than ISH tests. |
format | Online Article Text |
id | pubmed-3729815 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-37298152013-08-01 SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases Jacquemier, Jocelyne Spyratos, Frédérique Esterni, Benjamin Mozziconacci, Marie-Joëlle Antoine, Martine Arnould, Laurent Lizard, Sarab Bertheau, Philippe Lehmann-Che, Jacqueline Fournier, Cécile Blanc Krieger, Sophie Bibeau, Frédéric Lamy, Pierre-Jean Chenard, Marie Pierre Legrain, Michèle Guinebretière, Jean-Marc Loussouarn, Delphine MacGrogan, Gaëtan Hostein, Isabelle Mathieu, Marie Christine Lacroix, Ludovic Valent, Alexander Robin, Yves Marie Revillion, Françoise Triki, Magali Lacroix Seaume, Aline Salomon, Anne Vincent de Cremoux, Patricia Portefaix, Geneviève Xerri, Luc Vacher, Sophie Bièche, Ivan Penault-Llorca, Frédérique BMC Cancer Technical Advance BACKGROUND: Until now, FISH has been the gold standard technique to identify HER2 amplification status in ambiguous cases of breast cancer. Alternative techniques have been developed to increase the capacities of investigating HER2 amplification status. The aims of this multicenter study in a large series of breast cancer patients were to prospectively compare the level of performance of CISH, SISH, and qPCR alternative techniques on paraffin-embedded core biopsies with “gold standard FISH” for evaluation of HER2 amplification status. METHODS: This study was performed on 840 cases scored by immunohistochemistry (IHC): 0=317 (38%), 1+=183 (22%), 2+=109 (13%), 3+=231 (27%). Each of the 15 French centers participating in the study analyzed 56 breast carcinoma cases diagnosed on fixed paraffin-embedded core biopsies. HER2 amplification status was determined by commercially available FISH used as the reference technique with determination of the HER2/CEN17 ratio or HER2 copy number status. The alternative techniques performed on the same cases were commercially available SISH or CISH and a common qPCR method especially designed for the study including a set of 10 primer pairs: 2 for HER2 (exons 8 and 26), 5 to evaluate chromosome 17 polysomy TAOK1, UTP6, MRM1, MKS1, SSTR2 and 3 for diploidy control TSN, LAP3 and ADAMTS16. RESULTS: The concordance between IHC and FISH was 96% to 95% based on the HER2/CEN17 ratio (n=766) or HER2 copy number (n=840), respectively. The concordance of the alternative techniques with FISH was excellent: 97% and 98% for SISH (498 and 587 cases), 98% and 75% for CISH (108 and 204 cases) and 95% and 93% (699 and 773 cases) for qPCR based on the HER2/CEN17 ratio or HER2 copy number, respectively. Similarly, sensitivity ranged from 99% to 95% for SISH, 100% to 99% for CISH and 89% to 80% for qPCR. The concordance with FISH (ratio) in the 2+ cases was 89% for SISH, 100% for CISH and 93% for qPCR. CONCLUSION: These alternative techniques showed an excellent concordance with FISH in core biopsies allowing their use in routine clinical practice. This newly designed qPCR on paraffin-embedded core biopsies deserves special attention, as it is reliable, easy to perform and less expensive than ISH tests. BioMed Central 2013-07-22 /pmc/articles/PMC3729815/ /pubmed/23875536 http://dx.doi.org/10.1186/1471-2407-13-351 Text en Copyright © 2013 Jacquemier et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Technical Advance Jacquemier, Jocelyne Spyratos, Frédérique Esterni, Benjamin Mozziconacci, Marie-Joëlle Antoine, Martine Arnould, Laurent Lizard, Sarab Bertheau, Philippe Lehmann-Che, Jacqueline Fournier, Cécile Blanc Krieger, Sophie Bibeau, Frédéric Lamy, Pierre-Jean Chenard, Marie Pierre Legrain, Michèle Guinebretière, Jean-Marc Loussouarn, Delphine MacGrogan, Gaëtan Hostein, Isabelle Mathieu, Marie Christine Lacroix, Ludovic Valent, Alexander Robin, Yves Marie Revillion, Françoise Triki, Magali Lacroix Seaume, Aline Salomon, Anne Vincent de Cremoux, Patricia Portefaix, Geneviève Xerri, Luc Vacher, Sophie Bièche, Ivan Penault-Llorca, Frédérique SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases |
title | SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases |
title_full | SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases |
title_fullStr | SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases |
title_full_unstemmed | SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases |
title_short | SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases |
title_sort | sish/cish or qpcr as alternative techniques to fish for determination of her2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases |
topic | Technical Advance |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3729815/ https://www.ncbi.nlm.nih.gov/pubmed/23875536 http://dx.doi.org/10.1186/1471-2407-13-351 |
work_keys_str_mv | AT jacquemierjocelyne sishcishorqpcrasalternativetechniquestofishfordeterminationofher2amplificationstatusonbreasttumorscoreneedlebiopsiesamulticenterexperiencebasedon840cases AT spyratosfrederique sishcishorqpcrasalternativetechniquestofishfordeterminationofher2amplificationstatusonbreasttumorscoreneedlebiopsiesamulticenterexperiencebasedon840cases AT esternibenjamin sishcishorqpcrasalternativetechniquestofishfordeterminationofher2amplificationstatusonbreasttumorscoreneedlebiopsiesamulticenterexperiencebasedon840cases AT mozziconaccimariejoelle sishcishorqpcrasalternativetechniquestofishfordeterminationofher2amplificationstatusonbreasttumorscoreneedlebiopsiesamulticenterexperiencebasedon840cases AT antoinemartine sishcishorqpcrasalternativetechniquestofishfordeterminationofher2amplificationstatusonbreasttumorscoreneedlebiopsiesamulticenterexperiencebasedon840cases AT arnouldlaurent sishcishorqpcrasalternativetechniquestofishfordeterminationofher2amplificationstatusonbreasttumorscoreneedlebiopsiesamulticenterexperiencebasedon840cases AT lizardsarab sishcishorqpcrasalternativetechniquestofishfordeterminationofher2amplificationstatusonbreasttumorscoreneedlebiopsiesamulticenterexperiencebasedon840cases AT bertheauphilippe sishcishorqpcrasalternativetechniquestofishfordeterminationofher2amplificationstatusonbreasttumorscoreneedlebiopsiesamulticenterexperiencebasedon840cases AT lehmannchejacqueline sishcishorqpcrasalternativetechniquestofishfordeterminationofher2amplificationstatusonbreasttumorscoreneedlebiopsiesamulticenterexperiencebasedon840cases AT fourniercecileblanc sishcishorqpcrasalternativetechniquestofishfordeterminationofher2amplificationstatusonbreasttumorscoreneedlebiopsiesamulticenterexperiencebasedon840cases AT kriegersophie sishcishorqpcrasalternativetechniquestofishfordeterminationofher2amplificationstatusonbreasttumorscoreneedlebiopsiesamulticenterexperiencebasedon840cases AT bibeaufrederic sishcishorqpcrasalternativetechniquestofishfordeterminationofher2amplificationstatusonbreasttumorscoreneedlebiopsiesamulticenterexperiencebasedon840cases AT lamypierrejean sishcishorqpcrasalternativetechniquestofishfordeterminationofher2amplificationstatusonbreasttumorscoreneedlebiopsiesamulticenterexperiencebasedon840cases AT chenardmariepierre sishcishorqpcrasalternativetechniquestofishfordeterminationofher2amplificationstatusonbreasttumorscoreneedlebiopsiesamulticenterexperiencebasedon840cases AT legrainmichele sishcishorqpcrasalternativetechniquestofishfordeterminationofher2amplificationstatusonbreasttumorscoreneedlebiopsiesamulticenterexperiencebasedon840cases AT guinebretierejeanmarc sishcishorqpcrasalternativetechniquestofishfordeterminationofher2amplificationstatusonbreasttumorscoreneedlebiopsiesamulticenterexperiencebasedon840cases AT loussouarndelphine sishcishorqpcrasalternativetechniquestofishfordeterminationofher2amplificationstatusonbreasttumorscoreneedlebiopsiesamulticenterexperiencebasedon840cases AT macgrogangaetan sishcishorqpcrasalternativetechniquestofishfordeterminationofher2amplificationstatusonbreasttumorscoreneedlebiopsiesamulticenterexperiencebasedon840cases AT hosteinisabelle sishcishorqpcrasalternativetechniquestofishfordeterminationofher2amplificationstatusonbreasttumorscoreneedlebiopsiesamulticenterexperiencebasedon840cases AT mathieumariechristine sishcishorqpcrasalternativetechniquestofishfordeterminationofher2amplificationstatusonbreasttumorscoreneedlebiopsiesamulticenterexperiencebasedon840cases AT lacroixludovic sishcishorqpcrasalternativetechniquestofishfordeterminationofher2amplificationstatusonbreasttumorscoreneedlebiopsiesamulticenterexperiencebasedon840cases AT valentalexander sishcishorqpcrasalternativetechniquestofishfordeterminationofher2amplificationstatusonbreasttumorscoreneedlebiopsiesamulticenterexperiencebasedon840cases AT robinyvesmarie sishcishorqpcrasalternativetechniquestofishfordeterminationofher2amplificationstatusonbreasttumorscoreneedlebiopsiesamulticenterexperiencebasedon840cases AT revillionfrancoise sishcishorqpcrasalternativetechniquestofishfordeterminationofher2amplificationstatusonbreasttumorscoreneedlebiopsiesamulticenterexperiencebasedon840cases AT trikimagalilacroix sishcishorqpcrasalternativetechniquestofishfordeterminationofher2amplificationstatusonbreasttumorscoreneedlebiopsiesamulticenterexperiencebasedon840cases AT seaumealine sishcishorqpcrasalternativetechniquestofishfordeterminationofher2amplificationstatusonbreasttumorscoreneedlebiopsiesamulticenterexperiencebasedon840cases AT salomonannevincent sishcishorqpcrasalternativetechniquestofishfordeterminationofher2amplificationstatusonbreasttumorscoreneedlebiopsiesamulticenterexperiencebasedon840cases AT decremouxpatricia sishcishorqpcrasalternativetechniquestofishfordeterminationofher2amplificationstatusonbreasttumorscoreneedlebiopsiesamulticenterexperiencebasedon840cases AT portefaixgenevieve sishcishorqpcrasalternativetechniquestofishfordeterminationofher2amplificationstatusonbreasttumorscoreneedlebiopsiesamulticenterexperiencebasedon840cases AT xerriluc sishcishorqpcrasalternativetechniquestofishfordeterminationofher2amplificationstatusonbreasttumorscoreneedlebiopsiesamulticenterexperiencebasedon840cases AT vachersophie sishcishorqpcrasalternativetechniquestofishfordeterminationofher2amplificationstatusonbreasttumorscoreneedlebiopsiesamulticenterexperiencebasedon840cases AT biecheivan sishcishorqpcrasalternativetechniquestofishfordeterminationofher2amplificationstatusonbreasttumorscoreneedlebiopsiesamulticenterexperiencebasedon840cases AT penaultllorcafrederique sishcishorqpcrasalternativetechniquestofishfordeterminationofher2amplificationstatusonbreasttumorscoreneedlebiopsiesamulticenterexperiencebasedon840cases |